1. Pink Sheet
  2. >>Archive

In Brief

Prestige Brands growth argues against Genomma bid; Abbott Nutrition refutes China research report; FDA expects annual doubling of supplement AERs; FTC settles with acai online marketers; Schiff Nutrition revises full-year sales growth guidance upward; more news In Brief.

Prestige Brands Holdings Inc.expects sales in its current quarter will grow 38% year-over-year to $96.4 million, an announcement that comes as the OTC firm fends off a hostile takeover bid by Genomma Lab Internacional SAB de CV. In its fiscal 2012 fourth quarter ending March 31, Prestige projects adjusted net income will increase 84% to $11.8 million, though with the costs of acquiring and integrating brands from GlaxoSmithKline Consumer Healthcare LP, Prestige expects to report a net loss of about $2.3 million. Irvington, N.Y.-based Prestige has accused Genomma of trying to acquire it at a low price, before the value of the GSK deal is fully accretive ([A#05120319001]).

[Abbott Nutrition] refutes allegations by Hong Kong financial analysis firm CER Research that a Similac infant formula product in China...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 
• By Neena Brizmohun

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Nielsen Hobbs

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Nielsen Hobbs

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 
• By Francesca Bruce

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

Japan To Cut Leqembi Price By 15% Following Cost Effectiveness Review

 
• By Lisa Takagi

While Japanese government announces 8-15% price cuts for four drugs, including Leqembi, industry groups urge operational improvements to national cost effectiveness assessment scheme.

Precigen’s Papzimeous Approval Allows US FDA CBER Director To Emphasize Flexibility

 
• By Bridget Silverman

Returning FDA biologics center director Vinay Prasad used the Papzimeous approval announcement to reinforce his flexibility on rare disease therapies after several complete response letters and his brief departure from the agency.

Generic Drug Industry Seeks More US FDA Communication Reforms In GDUFA Renewal

 
• By Sue Sutter

Enhancing the consistency and clarity of information requests and discipline review letters, and improving assessment milestone communications are key areas targeted by generic drug makers for user fee program negotiations.